STERIS (STE) Competitors

STERIS logo
$257.42 -4.49 (-1.71%)
Closing price 03:59 PM Eastern
Extended Trading
$257.38 -0.04 (-0.01%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

STE vs. BSX, BDX, EW, IDXX, and GEHC

Should you buy STERIS stock or one of its competitors? STERIS's main competitors and comparable companies include Boston Scientific (BSX), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and GE HealthCare Technologies (GEHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Boston Scientific currently has a consensus target price of $61.43, suggesting a potential upside of 40.47%. STERIS has a consensus target price of $283.50, suggesting a potential upside of 8.27%. Given Boston Scientific's higher possible upside, equities analysts plainly believe Boston Scientific is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
2 Sell rating(s)
8 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.65
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Boston Scientific has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, STERIS has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Boston Scientific had 3 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Boston Scientific and 11 mentions for STERIS. Boston Scientific's average media sentiment score of 0.87 beat STERIS's score of 0.73 indicating that Boston Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
9 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
STERIS
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.16$2.90B$2.3618.53
STERIS$5.94B4.28$782.30M$8.4331.06

Boston Scientific has a net margin of 16.62% compared to STERIS's net margin of 13.41%. Boston Scientific's return on equity of 18.61% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific16.62% 18.61% 10.58%
STERIS 13.41%14.80%9.99%

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Boston Scientific beats STERIS on 10 of the 17 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Becton, Dickinson and Company presently has a consensus price target of $197.47, suggesting a potential downside of 8.72%. STERIS has a consensus price target of $283.50, suggesting a potential upside of 8.27%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.50
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

In the previous week, Becton, Dickinson and Company had 1 more articles in the media than STERIS. MarketBeat recorded 12 mentions for Becton, Dickinson and Company and 11 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 0.78 beat STERIS's score of 0.73 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
STERIS
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Becton, Dickinson and Company has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, STERIS has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

STERIS has a net margin of 13.41% compared to Becton, Dickinson and Company's net margin of 5.66%. Becton, Dickinson and Company's return on equity of 14.90% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company5.66% 14.90% 7.09%
STERIS 13.41%14.80%9.99%

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 1.9%. STERIS pays an annual dividend of $2.76 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays out 101.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 32.7% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 53 consecutive years and STERIS has raised its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$19.46B3.06$1.15B$4.1452.25
STERIS$5.94B4.28$782.30M$8.4331.06

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

STERIS beats Becton, Dickinson and Company on 11 of the 20 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

In the previous week, Edwards Lifesciences had 13 more articles in the media than STERIS. MarketBeat recorded 24 mentions for Edwards Lifesciences and 11 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 0.77 beat STERIS's score of 0.73 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
11 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Edwards Lifesciences has a net margin of 15.30% compared to STERIS's net margin of 13.41%. Edwards Lifesciences' return on equity of 16.06% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS13.41% 14.80% 9.99%
Edwards Lifesciences 15.30%16.06%12.36%

94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

STERIS currently has a consensus price target of $283.50, suggesting a potential upside of 8.27%. Edwards Lifesciences has a consensus price target of $109.88, suggesting a potential upside of 2.74%. Given STERIS's higher possible upside, equities research analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Edwards Lifesciences
0 Sell rating(s)
3 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.88

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.94B4.28$782.30M$8.4331.06
Edwards Lifesciences$6.07B10.13$1.07B$1.7760.42

Summary

Edwards Lifesciences beats STERIS on 11 of the 16 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

IDEXX Laboratories currently has a consensus target price of $717.27, suggesting a potential upside of 2.37%. STERIS has a consensus target price of $283.50, suggesting a potential upside of 8.27%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

In the previous week, STERIS had 5 more articles in the media than IDEXX Laboratories. MarketBeat recorded 11 mentions for STERIS and 6 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.55 beat STERIS's score of 0.73 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEXX Laboratories
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
STERIS
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IDEXX Laboratories has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, STERIS has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IDEXX Laboratories has a net margin of 25.36% compared to STERIS's net margin of 13.41%. IDEXX Laboratories' return on equity of 71.04% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
IDEXX Laboratories25.36% 71.04% 33.99%
STERIS 13.41%14.80%9.99%

IDEXX Laboratories has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$4.30B12.83$1.06B$14.8347.25
STERIS$5.94B4.28$782.30M$8.4331.06

Summary

IDEXX Laboratories beats STERIS on 10 of the 16 factors compared between the two stocks.

How does STERIS compare to GE HealthCare Technologies?

STERIS (NYSE:STE) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

STERIS pays an annual dividend of $2.76 per share and has a dividend yield of 1.1%. GE HealthCare Technologies pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. STERIS pays out 32.7% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has raised its dividend for 20 consecutive years and GE HealthCare Technologies has raised its dividend for 1 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS currently has a consensus price target of $283.50, indicating a potential upside of 8.27%. GE HealthCare Technologies has a consensus price target of $82.17, indicating a potential downside of 0.95%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
GE HealthCare Technologies
0 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.52

In the previous week, GE HealthCare Technologies had 1 more articles in the media than STERIS. MarketBeat recorded 12 mentions for GE HealthCare Technologies and 11 mentions for STERIS. STERIS's average media sentiment score of 0.73 beat GE HealthCare Technologies' score of 0.69 indicating that STERIS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GE HealthCare Technologies
1 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

STERIS has a net margin of 13.41% compared to GE HealthCare Technologies' net margin of 9.96%. GE HealthCare Technologies' return on equity of 20.45% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS13.41% 14.80% 9.99%
GE HealthCare Technologies 9.96%20.45%5.97%

GE HealthCare Technologies has higher revenue and earnings than STERIS. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.94B4.28$782.30M$8.4331.06
GE HealthCare Technologies$20.63B1.82$2.08B$4.7417.50

Summary

STERIS beats GE HealthCare Technologies on 13 of the 19 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$25.00B$5.95B$7.74B$22.85B
Dividend Yield1.09%1.69%2.46%3.79%
P/E Ratio30.5438.7734.1629.05
Price / Sales4.215.378.483.28
Price / Cash16.6823.9521.9315.51
Price / Book3.444.314.373.61
Net Income$782.30M$143.92M$3.52B$1.08B
7 Day Performance0.08%-4.88%-5.43%-3.75%
1 Month Performance15.80%-3.56%-4.54%-2.50%
1 Year Performance0.10%-0.40%-1.42%6.19%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.5651 of 5 stars
$257.42
-1.7%
$283.50
+10.1%
+1.2%$25.00B$5.94B30.5417,937
BSX
Boston Scientific
4.1937 of 5 stars
$44.00
+2.9%
$61.43
+39.6%
-57.4%$66.41B$20.07B14.3659,000
BDX
Becton, Dickinson and Company
3.6322 of 5 stars
$215.13
+1.5%
$195.47
-9.1%
+12.1%$57.64B$21.84B16.0972,000
EW
Edwards Lifesciences
2.8945 of 5 stars
$104.72
+2.5%
$108.88
+4.0%
+23.9%$57.22B$6.07B33.8016,000
IDXX
IDEXX Laboratories
2.4261 of 5 stars
$706.65
+4.5%
$717.27
+1.5%
+1.6%$55.04B$4.30B47.2011,000

Related Companies and Tools


This page (NYSE:STE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners